Central sleep apnea due to periodic breathing

Summary

Central sleep apnea due to periodic breathing (MONDO:0024359) is a disease. A subtype of central sleep apnea syndrome — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	central sleep apnea due to periodic breathing
Mondo ID	MONDO:0024359
SNOMED CT	85721000119105
UMLS	C3662057
MedGen	783212
Is cancer (heuristic)	no

Also known as: central sleep apnea due to periodic breathing · central sleep apnea with Cheyne–Stokes breathing · Cheyne–Stokes breathing

Disease family

This is a subtype of central sleep apnea syndrome. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › syndromic disease › central sleep apnea syndrome › central sleep apnea due to periodic breathing

Related subtypes (4): primary central sleep apnea syndrome, drug induced central sleep apnea, complex sleep apnea, central sleep apnea caused by high altitude

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.